METABOLIC SYNDROME IN ANTIRETROVIRAL THERAPY TREATMENT EXPERIENCED BY PEOPLE LIVING WITH HIV
Keywords:
Metabolic syndrome, HIV infection, antiretroviral therapyAbstract
Introduction: Metabolic syndrome (MS) constitutes a group of risk factors that significantly affect the quality of life and life expectancy of people living with HIV.
Aim: To estimate the prevalence of MS among people living with HIV who receive antiretroviral therapy (ART) in the Republic of North Macedonia (RNM).
Material and methods: A study was conducted on 53 adult patients with confirmed HIV infection at the University Clinic for Infectious Diseases and Febrile Conditions, who are receiving ART. In all patients, the presence of MS was determined according to the criteria of the National Cholesterol Education Program Adult Treatment Panel ATP III (NCEP ATP III), defined by at least three of five risk factors including: low values of HDL - high density lipoprotein cholesterol, elevated waist circumference, hypertriglyceridemia, increased values of fasting glucose and hypertension. The statistical analysis was made by utilizing the statistical program SPSS 23.0.
Results: The average age of patients was 35.7 ± 8.3, with a male predominance of 90.57%. All patients had undetectable values of HIV RNA viral load in serum and 79.25% had achieved immune reconstitution with a CD4 count above 350 cells/ml. The prevalence of MS among people living with HIV in RNM was 7.55%, or out of 53 respondents 4 had MS.
Conclusion: People with HIV infection in RNM who regularly receive ART have a low prevalence of metabolic syndrome.
References
HIV Data and Statistics. World Health Organization. 9th November 2022 https://www. who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics.
Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Women's Interagency HIV Study. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune DeficSyndr 2008; 48(3): 272-280. doi: 10.1097/QAI.0b013e31817af461.
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. CurrHypertens Rep 2018; 20(2): 12. doi: 10.1007/s11906-018-0812-z.
Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, et al. Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune DeficSyndr 2016; 73(4): 438-445. doi: 10.1097/QAI.0000000000001123.
Hamooya BM, Mulenga LB, Masenga SK, Fwemba I, Chirwa L, Siwingwa M, et al. Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors. Medicine (Baltimore) 2021; 100(14): e25236. doi: 10.1097/MD.0000000000025236.
Moyle G, Randell P. HIV and cardiovascular risk. Clin Med (Lond) 2008; 8(3): 315-318. doi: 10.7861/clinmedicine.8-3-315.
Lombo B, Alkhalil I, Golden MP, Fotjadhi I, Ravi S, Virata M, et al. Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy. Conn Med 2015; 79(5): 277-281. PMID: 26245015.
Mazzitelli M, Antoni MD, Castelli F, Ripamonti D, Zuglian G, Lapadula G, et al. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Medicine (Baltimore) 2022; 101(30): e29855. doi: 10.1097/MD.0000000000029855.
Osoti A, Temu TM, Kirui N, Ngetich EK, Kamano JH, Page S, et al. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. AIDS Patient Care STDS 2018; 32(6): 215-222. doi: 10.1089/apc.2018.0052.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute National High Blood Pressure Education Program NIH Publication No. 03-5233 December 2003.
Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One 2016; 11(3): e0150970. doi: 10.1371/journal.pone.0150970.
Iannone V, Passerotto RA, Lamanna F, Steiner RJ, Lombardi F, Salvo PF, et al. Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen. Viruses 2023; 15(5): 1046. doi: 10.3390/v15051046.
